alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 20.85 Disclosure to other Federal Government departments and agencies.

Any Food and Drug Administration (FDA) record otherwise exempt from public disclosure may be disclosed to other Federal Government departments and agencies, except that trade secrets and confidential commercial or financial information prohibited from disclosure by 21 U.S.C. 331(j), 21 U.S.C. 360j(c), 21 U.S.C. 360ll(d), 21 U.S.C. 360nn(e), and 21 U.S.C. 387f(c) may be released only as provided by those sections. Any disclosure under this section shall be pursuant to a written agreement that the record shall not be further disclosed by the other department or agency except with the written permission of FDA.

[87 FR 55913, Sept. 13, 2022]
Exhibit 32 (b)
 CERTIFICATION
PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
  (1)
    
    The Form 10-Q fully complies with the requirements of Section 13 (a) or
(15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78(d)); and(2)
    
    The information contained in the Form 10-Q fairly presents in all
material respects, the financial condition and results of operations of the
Partnership.
 Date: 11-14-08
 /s/ GARY S. JONESGary S. JonesPresident
 A signed original of this written statement required by Section 906 has been provided to Northland
Cable Properties Seven Limited Partnership and will be retained by Northland Cable Properties Seven
Limited Partnership and furnished to the Securities and Exchange Commission or its staff upon
request.
I 

118TH CONGRESS 

2D SESSION H. R. 7277 

To amend title 18, United States Code, to increase the time of imprisonment 

for an additional offense involving actual or perceived race, color, religion, 

or national origin. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2024 

Mr. D’ESPOSITO (for himself, Mr. NICKEL, Mr. LAWLER, and Mr. 

THANEDAR) introduced the following bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend title 18, United States Code, to increase the 

time of imprisonment for an additional offense involving 

actual or perceived race, color, religion, or national origin. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Halt Hate Act of 

5 2024’’. 

6 SEC. 2. PREVIOUS HATE CRIME ACTS. 

7 Section 249(a)(1)(B) of title 18, United States Code, 

8 is amended— 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7277 IH

1 (1) in clause (i), by striking ‘‘or’’ at the end; 

2 (2) in clause (ii), by striking the period at the 

3 end and inserting ‘‘; or’’; and 

4 (3) by adding at the end the following: 

5 ‘‘(iii) the defendant has previously 

6 been convicted of an offense under this 

7 paragraph or has been convicted of com8 mitting a State felony offense because of 

9 the actual or perceived race, color, religion, 

10 or national origin of any person.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.220 Flectol H. ( a ) Flectol H is the chemical 1,2-dihydro-2,2,4-trimethylquinoline, polymerized, C12H15N. It is a synthetic chemical not found in natural products, and has been used as a component of food packaging adhesives.
( b ) Food containing any added or detectable level of this substance is deemed to be adulterated in violation of the act based upon an order published in the Federal Register of April 7, 1967 (32 FR 5675).
[42 FR 14659, Mar. 15, 1977, as amended at 58 FR 17099, Apr. 1, 1993]
<PAGE>

EXHIBIT 31 (a)

I, John Whetzell certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Northland Cable
      Properties Seven Limited Partnership;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the registrant as of, and for, the periods presented in this
      quarterly report;

4.    The registrant's other certifying officer and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
      registrant and we have:

      a)    Designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this quarterly report is being prepared;

      b)    Evaluated the effectiveness of the registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures, as of
            the end of the period covered by this report based on such
            evaluation; and

      c)    Disclosed in this report any change in the registrant's internal
            controls over financial reporting that occurred during the
            registrant's most recent fiscal quarter that has materially
            affected, or is reasonably likely to affect, the registrant's
            internal controls over financial reporting; and

5.    The registrant's other certifying officer and I have disclosed, based on
      our most recent evaluation of internal controls over financial reporting,
      to the registrant's auditors and board of directors:

      a)    All significant deficiencies and material weaknesses in the design
            or operation of internal controls over financial reporting, which
            are reasonably likely to adversely affect the registrant's ability
            to record, process, summarize and report financial information; and

      b)    Any fraud, whether or not material that involves management or other
            employees who have a significant role in the registrant's internal
            controls over financial reporting.

DATE: 8-13-03

/s/  JOHN S. WHETZELL
     -----------------------------------
    John S. Whetzell
    Chief Executive Officer
NO UNPUBLISHED OPINIONS FILED TODAY.
Exhibit 21.1
  DOMESTIC SUBSIDIARIES OF THE COMPANY:
 STATE OFNAME OF SUBSIDIARY
    
    INCORPORATIONPCT International Holdings Inc.
    
    DelawareFlavors Holdings Inc.
    
    DelawareMafco Worldwide Corporation
    
    DelawareMafco Shanghai Corporation
    
    DelawareEVD Holdings Inc.
    
    DelawarePneumo Abex LLC
    
    DelawareConcord Pacific Corporation
    
    MainePneumo Abex Lessee Corp.
    
    DelawareCA Acquisition Holdings Inc.
    
    DelawareHarland Clarke Holdings Corp.
    
    DelawareHarland Clarke Corp.
    
    DelawareChecks In The Mail, Inc.
    
    DelawareHFS Scantron Holdings Corp.
    
    New YorkScantron Corporation
    
    DelawareHarland Financial Solutions, Inc.
    
    OregonHFS Research & Development, Inc.
    
    DelawareJohn H. Harland Company of Puerto Rico
    
    GeorgiaCentralia Holdings Corporation
    
    GeorgiaTransaction Holdings Inc.
    
    TennesseeTransaction Graphics Inc.
    
    TennesseeCheckboxes Direct Inc.
    
    TennesseeCreate-It!, Inc.
    
    IllinoisSubscriberMail, LLC
    
    Illinois
 FOREIGN SUBSIDIARIES OF THE COMPANY:
 NAME OF SUBSIDIARY
    
    JURISDICTIONEVD Holdings S.A.
    
    FranceExtraits Vegetaux Et Derives, S.A.
    
    FranceWei Feng Enterprises Ltd.
    
    British Virgin IslandsXianyang Concord Natural Products Co. Ltd.
    
    Peoples Republic of ChinaZhangjiagang Free Trade Zone MAFCO Liantai Biotech Co., Ltd.
    
    Peoples Republic of ChinaScantron Canada, Ltd.
    
    CanadaHarland Israel Ltd.
    
    IsraelHarland Financial Solutions Worldwide Limited
    
    Ireland
## APARTMEN TO F •'^^NSPORMTiO N • U ! O^^^* ^



## ^TTMAARTE N Directo r Offic e o f International U S Departmen t

o f Transportatio n 40 0 Sevent

h Stree t SW Roo m640 2 Washingto n D.C . 2059 0

U.S. A 1 Uwnummer : U w brie f van : Onsnumme r :^0S/l O Afd : DeptCA&S M Onderwerp : Air

Transport

Agreemen t 

### Phiiipsburg , DE C 1 3 201 0 Bijlagen : Dea r Mr . Sir s A s Ministe r

o f Tourism , Economi c Affairs , Traffi c & Telecommunication , th e undersigne dhereby , confirm s tha

t permissio n i s granted , o

n th e basi s o f

reciprocity , t o an y ai r

carrie r designate db y th e Unite d State s o f America , all right s t o conduc t flights to/fro mSt . Maarte n tha t are in th e conformit

y wit h th e Air transport Agreemen t

betwee n th e Kingdom^o f

th e Netherland s in respec t t o St . Maarte n an dth e Unite d State s o f America , signe dJul y 14 , 1998 . Sincere l

ikli n A . Meyer s Minister oflTourism , Economi c Affairs , Traffi c & Telecommunicatio n

Bestuurskantoo rCle m Labeg a Square Sin t Maarte n Phone : (599)542-223 3 / 542/253 5 fa x(599 ) 542-488 4
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.841 Polydextrose. Polydextrose as identified in this section may be safely used in food in accordance with the following prescribed conditions: ( a ) ( 1 ) Polydextrose (CAS Reg. No. 68424-04-4) is a partially metabolizable water-soluble polymer prepared by the condensation of a melt which consists either of approximately 89 percent D-glucose, 10 percent sorbitol, and 1 percent citric acid or of approximately 90 percent D-glucose, 10 percent sorbitol, and 0.1 percent phosphoric acid, on a weight basis.
( 2 ) Polydextrose may be partially neutralized with potassium hydroxide, or partially reduced by transition metal catalytic hydrogenation in aqueous solution.
( b ) The additive meets the specifications of the Food Chemicals Codex, 7th ed. (2010), pp. 811-814, which is incorporated by reference. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the United States Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852 (Internet address *http://www.usp.org*). Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030 or go to: *http://www.archives.gov/federal-register/cfr/ibr-locations.html .*
( c ) When standards of identity established under section 401 of the act do not preclude such use, polydextrose may be used in accordance with current good manufacturing practices as a bulking agent, formulation aid, humectant, and texturizer in all foods, except meat and poultry, baby food, and infant formula.
( d ) If the food containing the additive purports to be or is represented for special dietary uses, it shall be labeled in compliance with part 105 of this chapter.
( e ) The label and labeling of food a single serving of which would be expected to exceed 15 grams of the additive shall bear the statement: “Sensitive individuals may experience a laxative effect from excessive consumption of this product”.
[46 FR 30081, June 5, 1981, as amended at 59 FR 37421, July 22, 1994; 60 FR 54425, Oct. 24, 1995; 61 FR 14480, Apr. 2, 1996; 62 FR 30985, June 6, 1997; 63 FR 57597, Oct. 28, 1998; 65 FR 64605, Oct. 30, 2000; 65 FR 79719, Dec. 20, 2000; 72 FR 46564, Aug. 21, 2007; 78 FR 71464, Nov. 29, 2013; 88 FR 17721, Mar. 24, 2023]
§ 21.73 Accuracy, completeness, timeliness, and relevance of records disclosed from Privacy Act Record Systems. ( a ) The Food and Drug Administration shall make reasonable efforts to assure that a record about an individual in a Privacy Act Record System is accurate, relevant to a Food and Drug Administration purpose, timely, and complete before such record is disclosed under § 21.71.
( b ) Paragraph (a) of this section shall not apply to disclosures that are required under part 20 of this chapter (the public information regulations) or made to other Federal Government departments and agencies. Where appropriate, the letter disclosing the information shall indicate that the Food and Drug Administration has not reviewed the record to assure that it is accurate, relevant, timely, and complete.
Privacy Technology Demonstration

Contact Us: peoplescreening@hq.dhs.gov scitech.dhs.gov dhsscitech 07-2020

BIOMETRIC AND IDENTITY TECHNOLOGY 

CENTER

The Biometric and Identity Technology Center (BI-TC) 

serves as a resource for subject matter expertise in the 

science, methods, tools, and technologies used to 

recognize individuals and protect sensitive personal 

information. It enables Department of Homeland Security 

(DHS) components to cost-effectively maintain 

capabilities, enhance operations through effective use of 

new technologies, and inform strategic planning and 

acquisitions in developing new operational capabilities.

PRIVACY TECHNOLOGY DEMONSTRATION

Video technologies can enhance public safety and 

security, however there are legitimate concerns that these 

surveillance capabilities could be misused to recognize 

and track individuals. The DHS Science and Technology 

Directorate (S&T) is engaging industry to develop 

technologies to address public concerns that video 

surveillance capabilities could be misused for face 

recognition surveillance. Through the Biometric and 

Identity Technology Center, S&T will host a Privacy 

Technology Demonstration, a first- of-its kind event to 

examine the performance of technologies intended to 

protect the privacy of individuals by obfuscating or 

encrypting faces in videos.

The aim is to balance concerns, while allowing public 

safety organizations to safeguard our homeland.

DHS S&T is interested in understanding the product 

landscape of technologies that can assist in protecting the 

privacy of individuals in photos and videos.

PRIVACY TECHNOLOGY DEMONSTRATION 

DETAILS

The 2020 Privacy Technology Demonstration will take 

place during the Fall, in a laboratory test environment at 

S&T’s Maryland Test Facility (MdTF). The demonstration 

will evaluate full and partial identity obfuscation systems 

that are capable of collecting and/or processing live and/or 

stored video footage. Systems should output videos where 

the faces of individuals in the video stream or recording are 

obfuscated such that they cannot be re-identified by 

humans or face recognition systems. 

Examples of Video obfuscation technologies that may 

prevent individuals from being recognized by humans or 

machines in live or recorded videos may

 Blur, distort, or block face images 

 Replace face images with other images 

 Apply other masking techniques 

ADDITIONAL PROGRAM INFORMATION 

For more details about S&T’s Privacy Technology 

Demonstration, visit https://www.dhs.gov/science-andtechnology/privacy-technology-demonstration.
###### Editorial Note on Part 184

#### Editorial Note:

Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

#### § 184.1349 Karaya gum (sterculia gum).

(a) Karaya gum (sterculia gum) is the dried gummy exudate from the trunk of trees of various species of the genus *Sterculia.*

(b) The ingredient meets the specifications of the “Food Chemicals Codex,” 3d Ed. (1981), p. 157, which is incorporated by reference. Copies may be obtained from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.*

(c) The ingredient is used in food under the following conditions:

| Food (as served) | Percent | Function |
| --- | --- | --- |
| Frozen dairy desserts and mixes, § 170.3(n)(20) of this chapter | 0.3 | Formulation aid, § 170.3(o)(14) of this chapter; stabilizer and thickener, § 170.3(o)(28) of this chapter. |
| Milk products, § 170.3(n)(31) of this chapter | .02 | Stabilizer and thickener, § 170.3(o)(28) of this chapter. |
| Soft candy, § 170.3(n)(38) of this chapter | .9 | Emulsifier and emulsifier salt, § 170.3(o)(8) of this chapter; stabilizer and thickener, § 170.3(o)(28) of this chapter. |
| All other food categories | .002 | Formulation aid, § 170.3(o)(14) of this chapter; stabilizer and thickener, § 170.3(o)(28) of this chapter. |

Maximum Usage Levels Permitted

(d) [Reserved]

(e) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.

[42 FR 14653, Mar. 15, 1977, as amended at 42 FR 55205, Oct. 14, 1977; 49 FR 5612, Feb. 14, 1984]
Editorial Note on Part 112
Editorial Note: Nomenclature changes to part 112 appear at 81 FR 49896, July 29, 2016.

§ 112.204 What must I do if I receive an order to withdraw a qualified exemption applicable to my farm? The owner, operator, or agent in charge of a farm that receives an order to withdraw a qualified exemption applicable to that farm under § 112.5 must either: ( a ) Comply with applicable requirements of this part within 120 calendar days of the date from receipt of the order or, if operations have ceased and will not resume within 120 calendar days, before the beginning of operations in the next growing season, or within a reasonable timeframe, agreed to by FDA, based on a written justification, submitted to FDA, for a timeframe that exceeds 120 calendar days from the date of receipt of the order; or
( b ) Appeal the order within 15 calendar days of the date of receipt of the order in accordance with the requirements of § 112.206.
CONCURRENCES

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING SYMBOL

INITIALS/SIG 

DATE 

ROUTING LSYMBO

INITIALS/SIG 

DATE 

AD Grid Sheet 

Directorate Identifier: 2012-NM-018-AD 

AD Action: Emergency AD 

This action applies to certain airplanes originally manufactured by Lockheed for the 

military as P2V airplanes. 

If this draft is acceptable, please legibly sign the grid to the right with your first initial 

and full last name to show concurrence with this AD.
§ 206.10 Code imprint required. ( a ) Unless exempted under § 206.7, no drug product in solid oral dosage form may be introduced or delivered for introduction into interstate commerce unless it is clearly marked or imprinted with a code imprint that, in conjunction with the product's size, shape, and color, permits the unique identification of the drug product and the manufacturer or distributor of the product. Identification of the drug product requires identification of its active ingredients and its dosage strength. Inclusion of a letter or number in the imprint, while not required, is encouraged as a more effective means of identification than a symbol or logo by itself. Homeopathic drug products are required only to bear an imprint that identifies the manufacturer and their homeopathic nature.
( b ) A holder of an approved application who has, under § 314.70 (b) of this chapter, supplemented its application to provide for a new imprint is not required to bring its product into compliance with this section during the pendency of the agency's review. Once the review is complete, the drug product is subject to the requirements of the rule.
( c ) A solid oral dosage form drug product that does not meet the requirement for imprinting in paragraph (a) of this section and is not exempt from the requirement may be considered adulterated and misbranded and may be an unapproved new drug.
( d ) For purposes of this section, *code imprint* means any single letter or number or any combination of letters and numbers, including, e.g., words, company name, and National Drug Code, or a mark, symbol, logo, or monogram, or a combination of letters, numbers, and marks or symbols, assigned by a drug firm to a specific drug product.
[58 FR 47958, Sept. 13, 1993, as amended at 60 FR 19846, Apr. 21, 1995; 69 FR 18763, Apr. 8, 2004]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                       6,199,035
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               6,714,035
<CURRENT-LIABILITIES>                        5,162,800
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,551,235
<TOTAL-LIABILITY-AND-EQUITY>                 6,714,035
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                74,800
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (34,489)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (34,489)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (34,489)
<EPS-BASIC>                                      (.41)
<EPS-DILUTED>                                    (.41)



</TABLE>